Global Security Newswire
Daily News on Nuclear, Biological & Chemical Weapons, Terrorism and Related Issues
FDA OKs Generic Anthrax-Fighting Antibiotic
The U.S. Food and Drug Administration said this week it had approved generic forms of an antibiotic that could be used to treat anthrax infection (see GSN, April 21).
Twelve firms are now authorized to produce generic versions of the antibiotic Levaquin in tablet, liquid or injectable form. The drug can be used to treat adults for infection by inhalational anthrax, along with other bacterial infections affecting the bladder, kidneys, lungs, prostate, sinuses and skin, according to an FDA press release.
“Generic drugs are important options that allow greater access to health care for Americans,” Keith Webber, deputy head of the FDA Pharmaceutical Science Office, said in the release. “FDA-approved generic drugs must meet rigorous standards and are required to be of high quality so that people can be assured that their medications will act the same in the body as the brand-name product" (U.S. Food and Drug Administration release, June 20).
Note to our Readers
GSN ceased publication on July 31, 2014. Its articles and daily issues will remain archived and available on NTI’s website.
Oct. 6, 2014
The UNSCR 1540 Resource Collection examines implementation of United Nations Security Council Resolution 1540, which requires all states to implement measures aimed at preventing non-state actors from acquiring NBC weapons, related materials, and their means of delivery. It details implementation efforts in all of the regions and countries of the world to-date.
Remarks at side event to the PrepCom for the 2015 NPT Review Conference: “Change in Action: Overcoming Barriers to Non-Proliferation in the Middle East”
May 8, 2014
NTI Vice Chairman Des Browne addressed challenges to nonproliferation in the Middle East in a speech to members of The Middle East Next Generation of Arms Control Specialists network at a side event to the NPT PrepCom in New York.